ASRT
Price
$0.80
Change
-$0.01 (-1.23%)
Updated
Sep 5 closing price
Capitalization
76.78M
60 days until earnings call
RGEDF
Price
$29.25
Change
+$2.08 (+7.66%)
Updated
Sep 4 closing price
Capitalization
5.56B
Interact to see
Advertisement

ASRT vs RGEDF

Header iconASRT vs RGEDF Comparison
Open Charts ASRT vs RGEDFBanner chart's image
Assertio Holdings
Price$0.80
Change-$0.01 (-1.23%)
Volume$57.03K
Capitalization76.78M
Gedeon Richter
Price$29.25
Change+$2.08 (+7.66%)
Volume$3
Capitalization5.56B
ASRT vs RGEDF Comparison Chart in %
Loading...
ASRT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASRT vs. RGEDF commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASRT is a Hold and RGEDF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (ASRT: $0.80 vs. RGEDF: $29.25)
Brand notoriety: ASRT and RGEDF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ASRT: 24% vs. RGEDF: 100%
Market capitalization -- ASRT: $76.78M vs. RGEDF: $5.56B
ASRT [@Pharmaceuticals: Generic] is valued at $76.78M. RGEDF’s [@Pharmaceuticals: Generic] market capitalization is $5.56B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASRT’s FA Score shows that 0 FA rating(s) are green whileRGEDF’s FA Score has 1 green FA rating(s).

  • ASRT’s FA Score: 0 green, 5 red.
  • RGEDF’s FA Score: 1 green, 4 red.
According to our system of comparison, RGEDF is a better buy in the long-term than ASRT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASRT’s TA Score shows that 4 TA indicator(s) are bullish while RGEDF’s TA Score has 2 bullish TA indicator(s).

  • ASRT’s TA Score: 4 bullish, 4 bearish.
  • RGEDF’s TA Score: 2 bullish, 1 bearish.
According to our system of comparison, RGEDF is a better buy in the short-term than ASRT.

Price Growth

ASRT (@Pharmaceuticals: Generic) experienced а -4.47% price change this week, while RGEDF (@Pharmaceuticals: Generic) price change was +7.64% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

ASRT is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGEDF($5.56B) has a higher market cap than ASRT($76.8M). RGEDF YTD gains are higher at: 7.641 vs. ASRT (-8.415). RGEDF has higher annual earnings (EBITDA): 335B vs. ASRT (-8.66M). RGEDF has more cash in the bank: 150B vs. ASRT (98.2M). ASRT has less debt than RGEDF: ASRT (39.9M) vs RGEDF (21.6B). RGEDF has higher revenues than ASRT: RGEDF (903B) vs ASRT (117M).
ASRTRGEDFASRT / RGEDF
Capitalization76.8M5.56B1%
EBITDA-8.66M335B-0%
Gain YTD-8.4157.641-110%
P/E RatioN/A8.19-
Revenue117M903B0%
Total Cash98.2M150B0%
Total Debt39.9M21.6B0%
FUNDAMENTALS RATINGS
ASRT vs RGEDF: Fundamental Ratings
ASRT
RGEDF
OUTLOOK RATING
1..100
6850
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
10068
SMR RATING
1..100
9747
PRICE GROWTH RATING
1..100
5350
P/E GROWTH RATING
1..100
9941
SEASONALITY SCORE
1..100
5055

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGEDF's Valuation (2) in the null industry is somewhat better than the same rating for ASRT (67) in the Pharmaceuticals Major industry. This means that RGEDF’s stock grew somewhat faster than ASRT’s over the last 12 months.

RGEDF's Profit vs Risk Rating (68) in the null industry is in the same range as ASRT (100) in the Pharmaceuticals Major industry. This means that RGEDF’s stock grew similarly to ASRT’s over the last 12 months.

RGEDF's SMR Rating (47) in the null industry is somewhat better than the same rating for ASRT (97) in the Pharmaceuticals Major industry. This means that RGEDF’s stock grew somewhat faster than ASRT’s over the last 12 months.

RGEDF's Price Growth Rating (50) in the null industry is in the same range as ASRT (53) in the Pharmaceuticals Major industry. This means that RGEDF’s stock grew similarly to ASRT’s over the last 12 months.

RGEDF's P/E Growth Rating (41) in the null industry is somewhat better than the same rating for ASRT (99) in the Pharmaceuticals Major industry. This means that RGEDF’s stock grew somewhat faster than ASRT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASRTRGEDF
RSI
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
50%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
33%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
35%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
24%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
20%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
N/A
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
80%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ASRT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EHSI1.210.15
+14.19%
Elite Health Systems, Inc.
BICEY31.390.70
+2.28%
BIC SA
CAHPF6.300.05
+0.80%
Evolution Mining Ltd.
PESAF2.34N/A
N/A
Panoro Energy ASA
BGPPF0.01N/A
N/A
CRAFT 1861 Global Holdings Inc.

ASRT and

Correlation & Price change

A.I.dvisor tells us that ASRT and RGEDF have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ASRT and RGEDF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASRT
1D Price
Change %
ASRT100%
-1.19%
RGEDF - ASRT
31%
Poorly correlated
N/A
SNOA - ASRT
28%
Poorly correlated
+4.42%
COLL - ASRT
27%
Poorly correlated
-2.32%
LFCR - ASRT
24%
Poorly correlated
-5.16%
CPHI - ASRT
24%
Poorly correlated
+16.32%
More

RGEDF and

Correlation & Price change

A.I.dvisor tells us that RGEDF and ASRT have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGEDF and ASRT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGEDF
1D Price
Change %
RGEDF100%
N/A
ASRT - RGEDF
31%
Poorly correlated
-1.19%
OILFF - RGEDF
11%
Poorly correlated
-10.49%
OWPC - RGEDF
4%
Poorly correlated
-0.25%
ROMJF - RGEDF
3%
Poorly correlated
-4.79%
SGIOF - RGEDF
3%
Poorly correlated
N/A
More